OverviewCoherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
|08/08/18||Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results|
|REDWOOD CITY, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018.
Second Quarter 2018 Corporate Highlights Include:
UDENYCA™ (pegfilgrastim-cbqv), biosimilar candidate to Neulasta®
• On May 3, 2018, Coherus announced the re-submission of its biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) under the 351(k... |
|07/27/18||Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)|
|REDWOOD CITY, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®1) biosimilar candidate. UDENYCA has the opportunity to become one of the first pegfilgrastim biosimilars to gain Marketing Authorization in Europe.
"The positive ... |
|07/25/18||Coherus BioSciences Announces New Employment Inducement Grants|
|REDWOOD CITY, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective July 19, 2018, the compensation committee of the company’s board of directors granted 11 new employees options to purchase an aggregate of 167,500 shares of the company’s common stock with a per share exercise price of $18.45, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commence... |
|07/24/18||Coherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th|
|REDWOOD CITY, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2018 financial results will be released after market close on Wednesday, August 8, 2018. Starting at 4:30 p.m. ET, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing second quarter 2018 financial results, we will post them on the Coherus website at http://investors.cohe... |
|There are currently no events scheduled.|
Receive E-mail Alerts
|Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.|